NCT00617032View on ClinicalTrials.gov

Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions
Rheumatoid Arthritis
Interventions
GENETIC

tgAAC94 gene therapy vector

Single Dose 1x10\^10 DNase resistant particles (DRP) / mL joint volume

GENETIC

tgAAC94 gene therapy vector

Single dose 1x10\^11 DNase resistant particles (DRP) / mL joint volume

GENETIC

tgAAC94 placebo

Single dose

Trial Locations (7)

Unknown

UCLA Division of Rheumatology, Los Angeles

Denver Arthritis Research Center, Denver

Swedish Rheumoatology Research, Seattle

Arthritis Research Centre of Canada, Vancouver

Arthritis Centre Clinical Research Unit UofManitoba, Winnipeg

Mt Sinai Hospital, Toronto

Toronto Western Hospital, Toronto

All Listed Sponsors
lead

Targeted Genetics Corporation

INDUSTRY

NCT00617032 - Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94 | Biotech Hunter | Biotech Hunter